MA34738B1 - Neutralisation d'anticorps anti-ccl20 - Google Patents

Neutralisation d'anticorps anti-ccl20

Info

Publication number
MA34738B1
MA34738B1 MA36013A MA36013A MA34738B1 MA 34738 B1 MA34738 B1 MA 34738B1 MA 36013 A MA36013 A MA 36013A MA 36013 A MA36013 A MA 36013A MA 34738 B1 MA34738 B1 MA 34738B1
Authority
MA
Morocco
Prior art keywords
antibodies
ccl20
relates
neutralization
present
Prior art date
Application number
MA36013A
Other languages
English (en)
Inventor
Toshio Imai
James Bradford Kline
Tetsu Kawano
Luigi Grasso
Yoshimasa Sakamoto
Jared Spidel
Miyuki Nishimura
Kenzo Muramoto
Tatsuo Horizoe
Original Assignee
Horizoe Tastuo
Toshio Imai
James Bradford Kline
Tetsu Kawano
Luigi Grasso
Yoshimasa Sakamoto
Jared Spidel
Miyuki Nishimura
Kenzo Muramoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizoe Tastuo, Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto filed Critical Horizoe Tastuo
Publication of MA34738B1 publication Critical patent/MA34738B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

La présente invention concerne de nouveaux anticorps humanisés, chimères et murins ayant une spécificité de liaison au ligand 20 de la chimiokine CC humaine (CCL20). La présente invention concerne en outre des chaînes lourdes et des chaînes légères desdits anticorps. L'invention concerne également des acides nucléiques isolés, des vecteurs recombinants et des cellules hôtes comprenant une séquence codant pour une chaîne lourde et/ou une chaîne légère desdits anticorps, et un procédé de préparation desdits anticorps. Les anticorps anti-CCL20 de l'invention peuvent être utilisés dans des applications thérapeutiques destinées à traiter, par exemple, des troubles inflammatoires et autoimmuns et le cancer.
MA36013A 2010-11-19 2013-06-14 Neutralisation d'anticorps anti-ccl20 MA34738B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41561410P 2010-11-19 2010-11-19
PCT/US2011/061525 WO2012068540A2 (fr) 2010-11-19 2011-11-18 Neutralisation d'anticorps anti-ccl20

Publications (1)

Publication Number Publication Date
MA34738B1 true MA34738B1 (fr) 2013-12-03

Family

ID=46084688

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36013A MA34738B1 (fr) 2010-11-19 2013-06-14 Neutralisation d'anticorps anti-ccl20

Country Status (25)

Country Link
US (3) US8491901B2 (fr)
EP (1) EP2640744A4 (fr)
JP (3) JP5996549B2 (fr)
KR (1) KR101919170B1 (fr)
CN (1) CN103874707B (fr)
AR (1) AR084141A1 (fr)
AU (2) AU2011329647B2 (fr)
BR (1) BR112013012396A2 (fr)
CA (1) CA2818548A1 (fr)
CL (1) CL2013001403A1 (fr)
CO (1) CO6761352A2 (fr)
CR (1) CR20130228A (fr)
DO (1) DOP2013000111A (fr)
EA (1) EA029419B1 (fr)
IL (1) IL226383B (fr)
MA (1) MA34738B1 (fr)
MX (1) MX361929B (fr)
NZ (1) NZ611269A (fr)
PE (2) PE20180249A1 (fr)
PH (1) PH12013500990A1 (fr)
SG (2) SG191716A1 (fr)
TW (1) TWI589587B (fr)
UA (1) UA114077C2 (fr)
WO (1) WO2012068540A2 (fr)
ZA (3) ZA201303571B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG191716A1 (en) * 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
SG11201404354UA (en) 2012-02-17 2014-10-30 Seattle Genetics Inc ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
EP2906295A4 (fr) * 2012-10-15 2016-06-01 Oncomed Pharm Inc Méthodes de traitement de maladies oculaires
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
CN106413751A (zh) 2014-05-21 2017-02-15 辉瑞大药厂 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
EP3233112A2 (fr) * 2014-12-17 2017-10-25 Cancer Research Technology Limited Molécules d'anticorps anti-cxcl12 et leurs utilisations
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
ES2776243T3 (es) 2015-06-03 2020-07-29 Medical College Wisconsin Inc Un polipéptido de dímero CCL20 bloqueado modificado por ingeniería
RU2729396C2 (ru) * 2015-07-14 2020-08-06 МЕДИММЬЮН, ЭлЭлСи Композиции и способы лечения рака
WO2017064564A2 (fr) * 2015-10-16 2017-04-20 Glaxosmithkline Intellectual Property Limited Régimes thérapeutiques pour traiter l'arthrite psoriatique avec un anticorps anti-ccl20
US11305010B2 (en) * 2016-01-21 2022-04-19 The Scripps Research Institute Synthetic opioid vaccine
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
IL315266A (en) 2016-06-14 2024-10-01 Merck Sharp ַ& Dohme Llc Anti-coagulation factor xi antibodies
EP3560957A4 (fr) * 2016-11-14 2020-10-21 Dinona Anticorps se liant spécifiquement à cd66c et utilisation associée
FR3072779A1 (fr) * 2017-10-19 2019-04-26 Sinnovial Procede d'estimation de l'efficacite d'un modulateur de la costimulation des lymphocytes t contre la polyarthrite rhumatoide apres reponse inadequate a une biotherapie
WO2019094608A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps anti-bace1 et leurs procédés d'utilisation
EP3706795A4 (fr) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. Méthodes et compositions pour la génération et l'utilisation d'anticorps tau phosphorylés spécifiques à une conformation humanisée
WO2020185952A1 (fr) * 2019-03-11 2020-09-17 xCella Biosciences, Inc. Anticorps se liant à cd27 et leurs utilisations
US11827709B2 (en) 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
US12129302B2 (en) 2021-08-25 2024-10-29 Ibio, Inc. Anti-CD-25 antibody
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN120518761B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
CN119139478A (zh) * 2024-10-11 2024-12-17 首都医科大学附属北京胸科医院 一种治疗anxa6+egfr突变的肺腺癌的组合物

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4897348A (en) 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
WO1989007142A1 (fr) 1988-02-05 1989-08-10 Morrison Sherie L Anticorps a region constante a modification de domaine
FI903931A7 (fi) 1988-12-08 1990-08-08 Sandoz Ag Neutrofiiliaktivoiva peptidi-2
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5212073A (en) 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
CA2064558C (fr) 1989-09-25 2001-01-30 Ian B. Pragnell Methode d'inhibition de la croissance de cellules souches
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ATE177472T1 (de) 1990-09-14 1999-03-15 Chiron Corp Expression von makrophagen-induzierbaren proteinen (mips) in hefezellen
US6001649A (en) 1990-11-29 1999-12-14 Societe Anonyme: Elf Sanofi Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
US5401651A (en) 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
US5306709A (en) 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5346686A (en) 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
US5413778A (en) 1992-10-05 1995-05-09 The Regents Of The University Of Michigan Labelled monocyte chemoattractant protein material and medical uses thereof
WO1994019935A1 (fr) 1993-03-09 1994-09-15 Genzyme Corporation Isolement de constituants d'interet du lait
US5474983A (en) 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
WO1994026087A2 (fr) 1993-05-14 1994-11-24 Connor Kim C O Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH0789866A (ja) 1993-09-21 1995-04-04 Nippon Kayaku Co Ltd 感染防御剤
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE262914T1 (de) 1993-12-22 2004-04-15 Human Genome Sciences Inc Entzündungsproteine aus makrophagen mip-3, mip-4 und mip-1gamma
EP0770086A4 (fr) 1994-05-16 1998-07-15 Human Genome Sciences Inc Facteur-3 inhibiteur de la migration des macrophages
DE69428460T2 (de) 1994-05-16 2002-05-23 Human Genome Sciences, Inc. Chemotaktisches protein
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
ES2216001T3 (es) 1994-08-23 2004-10-16 Human Genome Sciences, Inc. Polipeptidos de quimioquina humana.
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
AU708558B2 (en) 1994-08-23 1999-08-05 Human Genome Sciences, Inc. Human chemokine beta-9
DE69433648T2 (de) 1994-08-23 2005-02-17 Human Genome Sciences, Inc. Menschliche chemokin-polypeptide
DE69434900D1 (de) 1994-08-23 2007-02-08 Human Genome Sciences Inc Menschliche chemokin-polypeptide
US5981230A (en) 1994-08-23 1999-11-09 Human Genome Sciences, Inc. Polynucleotide encoding chemokine β-4
WO1996009062A1 (fr) 1994-09-23 1996-03-28 University Of Nebraska Board Of Regents Agonistes et antagonistes polypeptidiques de l'interleukine-8 humaine
JP4046349B2 (ja) 1994-11-07 2008-02-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子−γ
US5602008A (en) 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
JPH11507205A (ja) 1995-04-27 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体
CN1190991A (zh) 1995-06-05 1998-08-19 人类基因组科学公司 人类趋化因子β－11和人类趋化因子α－1
AU713267B2 (en) 1995-06-06 1999-11-25 Human Genome Sciences, Inc. Human chemokine beta-13
AU2698795A (en) 1995-06-06 1996-12-24 Human Genome Sciences, Inc. Human chemokine beta-12
ZA968897B (en) 1995-10-24 1998-07-14 Smithkline Beecham Corp Novel chemokine for mobilizing stem cells
ZA968896B (en) 1995-10-24 1997-04-24 Smithkline Beecham Corp Method of mobilizing hematopoietic stem cells
WO1997031098A1 (fr) 1996-02-23 1997-08-28 Human Genome Sciences, Inc. Polypeptides de chemokine humaine
WO1997033904A1 (fr) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Recepteurs contenant un domaine de mort cellulaire
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP2000508527A (ja) 1996-03-27 2000-07-11 アイコス コーポレイション 単球走化性タンパク質―５物質及び方法
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
JP2000514295A (ja) 1996-07-05 2000-10-31 シェーリング コーポレイション 哺乳動物のケモカイン試薬
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
ATE412740T1 (de) 1996-08-16 2008-11-15 Human Genome Sciences Inc Menschliches alpha-endokin
GB9617923D0 (en) 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
AU4243097A (en) 1996-09-10 1998-04-02 Schering Corporation Mammalian chemokines, related reagents
WO1998014573A1 (fr) 1996-09-30 1998-04-09 The General Hospital Corporation Nouvelles chimiokines mcp-4 et mcp-5
WO1998017800A1 (fr) 1996-10-17 1998-04-30 Shionogi & Co., Ltd. Larc, nouvelle chimiokine cc humaine
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
CN1213401A (zh) 1996-11-15 1999-04-07 先进研究及技术学会 Exodus化学激活素物质及方法
US7101987B2 (en) * 1996-11-27 2006-09-05 Schering Corporation CCL27 polypeptides
CA2277925A1 (fr) 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Recepteurs 6.alpha. et 6.beta. du facteur de necrose tumorale
JP2001505060A (ja) 1997-01-14 2001-04-17 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 腫瘍壊死因子受容体 ５
PT1012274E (pt) 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
JP4330180B2 (ja) 1997-03-17 2009-09-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
US6972323B1 (en) * 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
EP0979282A1 (fr) 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Chemokine st38.2 du rat
EP0983303B1 (fr) 1997-05-21 2006-03-08 Biovation Limited Procede de production de proteines non immunogenes
CA2292790A1 (fr) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Recepteur tr10 du facteur de necrose tumorale humain
CA2295991A1 (fr) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Recepteur humain tr9 du facteur de necrose tumorale
JP2002533056A (ja) 1998-03-18 2002-10-08 コリクサ コーポレイション 肺癌の治療および診断のための化合物および方法
EP1105427A2 (fr) 1998-08-17 2001-06-13 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6645491B1 (en) 1999-02-03 2003-11-11 Schering Corporation Method for treating inflammatory conditions using an antibody to MIP-3α
JP2002540068A (ja) * 1999-02-03 2002-11-26 シェーリング コーポレイション 治療におけるｍｉｐ−３ａのアゴニストまたはアンタゴニストの使用
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US20040197329A1 (en) 2000-10-13 2004-10-07 Yasunori Nakayama Remedies or preventives for rheumatoid arthritis
ATE320450T1 (de) 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
CA2449628C (fr) 2001-06-07 2008-05-06 Zheng Wei Technique de migration cellulaire
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7375192B2 (en) 2002-05-01 2008-05-20 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
CA2514117A1 (fr) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition et methode destinees a traiter les maladies de demyelinisation et la paralysie par administration d'agents de remyelinisation
WO2005017149A1 (fr) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique
US7264806B2 (en) 2003-11-01 2007-09-04 Biovation Ltd. Modified anti-CD52 antibody
US7811563B2 (en) * 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
JP2009096716A (ja) * 2006-01-19 2009-05-07 Eisai R & D Management Co Ltd 抗ｃｃｌ２０抗体による自己免疫疾患の治療
CA2700197C (fr) * 2007-11-08 2020-09-08 Neogenix Oncology, Inc. Anticorps monoclonaux recombinants et antigenes correspondants pour des cancers du colon et du pancreas
AU2008337517B2 (en) * 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
EP2296705A1 (fr) * 2008-06-24 2011-03-23 Hadasit Medical Research Services And Development Ltd. Anticorps spécifiques de ccl20 pour la thérapie du cancer
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
SG191716A1 (en) * 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
WO2013005649A1 (fr) * 2011-07-01 2013-01-10 協和発酵キリン株式会社 Anticorps anti-ccr6 humain
JP7089866B2 (ja) 2017-12-22 2022-06-23 セーレン株式会社 開口部を有するシート状物およびその製造方法

Also Published As

Publication number Publication date
US20160046707A1 (en) 2016-02-18
US20140045215A1 (en) 2014-02-13
AR084141A1 (es) 2013-04-24
CN103874707B (zh) 2017-04-19
AU2016200359B2 (en) 2018-05-24
DOP2013000111A (es) 2014-06-15
KR101919170B1 (ko) 2018-11-15
JP6289520B2 (ja) 2018-03-07
CA2818548A1 (fr) 2012-05-24
JP2016093195A (ja) 2016-05-26
UA114077C2 (xx) 2017-04-25
ZA201303571B (en) 2014-12-23
IL226383A0 (en) 2013-07-31
TWI589587B (zh) 2017-07-01
US8491901B2 (en) 2013-07-23
CO6761352A2 (es) 2013-09-30
MX2013005532A (es) 2013-09-26
JP2018042578A (ja) 2018-03-22
EA201390738A1 (ru) 2013-12-30
ZA201701051B (en) 2018-05-30
US9133273B2 (en) 2015-09-15
WO2012068540A2 (fr) 2012-05-24
US20120148592A1 (en) 2012-06-14
MX361929B (es) 2018-12-19
PH12013500990A1 (en) 2022-11-23
SG10201509499RA (en) 2015-12-30
AU2011329647B2 (en) 2015-10-22
JP2014502154A (ja) 2014-01-30
CL2013001403A1 (es) 2014-08-08
KR20130135872A (ko) 2013-12-11
AU2011329647A1 (en) 2013-05-02
EP2640744A4 (fr) 2014-05-28
PE20180249A1 (es) 2018-02-02
PE20140633A1 (es) 2014-05-30
CN103874707A (zh) 2014-06-18
CR20130228A (es) 2013-09-18
ZA201406017B (en) 2017-06-28
WO2012068540A3 (fr) 2012-09-27
TW201305204A (zh) 2013-02-01
AU2016200359A1 (en) 2016-02-11
BR112013012396A2 (pt) 2020-11-10
JP5996549B2 (ja) 2016-09-21
US9809647B2 (en) 2017-11-07
EP2640744A2 (fr) 2013-09-25
SG191716A1 (en) 2013-08-30
EA029419B1 (ru) 2018-03-30
IL226383B (en) 2018-07-31
NZ611269A (en) 2015-03-27

Similar Documents

Publication Publication Date Title
MA34738B1 (fr) Neutralisation d'anticorps anti-ccl20
MA32621B1 (fr) Traitement de maladie auto-immune et inflammatoire
MA37949A1 (fr) Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite
MA34383B1 (fr) Analogues de glucagon
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
EA200900424A1 (ru) Человеческие антитела, которые связываются с cxcr4, и их применение
MA43459A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA43330B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA28982B1 (fr) Anticorps antagonistes de il-17
MA33717B1 (fr) Immunoconjugués ciblés
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA49355A (fr) Formats de récepteurs de liaison d'antigène améliorés
MA43322A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
WO2003104399A3 (fr) Gene lie au cancer servant de cible en chimiotherapie
MA46647A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
EP2532365A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
EP2532366A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA34053B1 (fr) Polypeptides agonistes de liaison à dr5
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
FR3132634B1 (fr) Composés bifonctionnels ciblant le récepteur du mannose 6-phosphate cation-indépendant
MA33668B1 (fr) Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer